BPH Pathophysiology: Updated Molecular Mechanisms
- Basic pathophysiology – hyperplasia of the transitional zone
- Role of DHT – 5-alpha reductase and androgen signalling
- Role of estrogen – estrogen sensitisation
- Chronic inflammation – a key driver
- Growth factors – EGF, FGF, TGF-beta, IGF-1
- Stem cells and BPH development
- Smooth muscle contraction – alpha-1 adrenergic receptors
- Genetic factors – heritability and gene variants
- Interactive FAQ – 9 questions about BPH pathophysiology
Basic pathophysiology – hyperplasia of the transitional zone
BPH (benign prostatic hyperplasia) is characterised by an increase in the number of epithelial and stromal cells in the transitional zone and periurethral glands. This is not hypertrophy (enlargement of individual cells) but true hyperplasia.
- Stromal hyperplasia: Increase in smooth muscle cells and fibroblasts (accounts for most volume increase)
- Epithelial hyperplasia: Increase in glandular cells
- Nodular growth: Discrete nodules rather than uniform enlargement
Role of DHT – 5-alpha reductase and androgen signalling
Dihydrotestosterone (DHT) is the primary androgen driving prostate growth.
5-alpha reductase enzymes:
- Type 1: Located in the liver and skin (not prostate)
- Type 2: Located in the prostate (epithelial cells) – converts testosterone to DHT
- Type 3: Recently discovered, minor role
DHT effects:
- Binds to androgen receptors with 5-10x higher affinity than testosterone
- Stimulates cell proliferation and inhibits apoptosis
- DHT levels in the prostate remain high even as serum testosterone declines with age
Evidence for DHT's role:
- Men with 5-alpha reductase type 2 deficiency have very small prostates and never develop BPH
- 5-alpha reductase inhibitors (finasteride, dutasteride) shrink the prostate by 20-30%
Role of estrogen – estrogen sensitisation
With aging, testosterone levels decline, but estrogen levels remain stable, leading to a relative estrogen excess.
- Estrogen receptor alpha (ERα): Mediates proliferative effects
- Estrogen receptor beta (ERβ): May have protective effects (loss of ERβ in BPH)
- Mechanism: Estrogen sensitises the prostate to DHT, promoting growth
- Inflammation: Estrogen also induces chronic inflammation
Chronic inflammation – a key driver
Chronic inflammation is now recognised as a central driver of BPH progression.
- Prevalence: Up to 80% of BPH surgical specimens show chronic inflammation
- Inflammatory cells: Lymphocytes (CD4+, CD8+), macrophages
- Cytokines: IL-8, IL-6, TNF-alpha, COX-2
- Mechanism: Inflammatory cytokines stimulate prostate cell proliferation and inhibit apoptosis
- Triggers:
- Urine reflux into prostatic ducts
- Autoimmune reactions
- Oxidative stress
- Dietary factors
Clinical correlation:
- Men with chronic inflammation on biopsy have larger prostates and worse symptoms
- Inflammation predicts poor response to 5-ARIs
Growth factors – EGF, FGF, TGF-beta, IGF-1
Growth factors mediate the effects of hormones and inflammation on prostate cell proliferation.
- EGF (Epidermal Growth Factor): Stimulates epithelial cell proliferation
- FGF (Fibroblast Growth Factor):
- FGF-2 (bFGF): Stromal cell proliferation
- FGF-7 (KGF): Epithelial cell proliferation
- TGF-beta (Transforming Growth Factor-beta): Complex role – inhibits epithelial growth but stimulates stromal growth
- IGF-1 (Insulin-like Growth Factor-1): Promotes cell proliferation, inhibits apoptosis
- VEGF (Vascular Endothelial Growth Factor): Promotes angiogenesis (blood vessel growth)
Stem cells and BPH development
The prostate contains stem cells that can differentiate into epithelial or stromal cells. BPH may result from stem cell dysregulation.
- Prostatic stem cells: Located in the basal cell layer
- Markers: CD133, CD44, integrin α2β1, CK5, CK14
- Proposed mechanism: Stem cells may be reprogrammed to proliferate excessively, leading to hyperplasia
- Stromal-epithelial interactions: Paracrine signalling between stroma and epithelium is critical
Smooth muscle contraction – alpha-1 adrenergic receptors
BPH causes urinary obstruction through both static (enlargement) and dynamic (muscle tone) components.
- Alpha-1 adrenergic receptors: Located on prostate smooth muscle and bladder neck
- Subtypes: Alpha-1A (prostate – 70%), Alpha-1B (blood vessels), Alpha-1D (bladder)
- Stimulation: Norepinephrine causes smooth muscle contraction → increased urethral resistance
- Clinical correlation: Alpha-blockers (tamsulosin, alfuzosin) relax smooth muscle, improving urine flow within days
Genetic factors – heritability and gene variants
BPH has a significant genetic component.
- Heritability: 40-50% (twin studies)
- Family history: First-degree relatives with BPH have 2-3x higher risk
- Gene variants:
- Androgen receptor gene (AR) polymorphisms (CAG repeats)
- 5-alpha reductase type 2 (SRD5A2) variants
- Vitamin D receptor (VDR) polymorphisms
- Inflammation-related genes (IL-8, COX-2)
Interactive FAQ – BPH pathophysiology
Hyperplasia (increased cell number) of the transitional zone of the prostate, involving both epithelial and stromal cells.
DHT is the primary androgen driving prostate growth. It binds to androgen receptors, stimulating cell proliferation.
Chronic inflammation (present in 80% of BPH specimens) releases cytokines that stimulate cell proliferation and inhibit apoptosis.
They block alpha-1 adrenergic receptors on prostate smooth muscle, reducing dynamic obstruction (muscle tone).
Yes – heritability is 40-50%. First-degree relatives have 2-3x higher risk.
Relative estrogen excess with aging sensitises the prostate to DHT and induces chronic inflammation.
EGF, FGF-2, FGF-7, TGF-beta, IGF-1, and VEGF – stimulate proliferation, inhibit apoptosis, and promote angiogenesis.
Yes – prostatic stem cells may be dysregulated, leading to excessive proliferation of epithelial and stromal cells.
Static obstruction: prostate enlargement physically compresses the urethra. Dynamic obstruction: smooth muscle contraction increases resistance.
Disclaimer: This information is for educational purposes and intended for clinicians and researchers. BPH pathophysiology is complex and multifactorial.